New preclinical findings show AI-discovered T-cell epitopes may improve control of CMV infection, adding to earlier evidence supporting the multi-component vaccine strategy’s potential to address a virus closely linked to congenital hearing loss....
No actionable change — this is early-stage preclinical (animal/lab) data with no human trials completed; audiologists cannot apply these findings to current practice.
CMV is the leading non-genetic cause of congenital hearing loss, so a successful vaccine could meaningfully reduce the incidence of hearing impairment in newborns over the long term.
- 01EVX-V1 is an AI-designed vaccine targeting cytomegalovirus (CMV), a leading infectious cause of congenital hearing loss.
- 02The data presented are preclinical (animal/lab stage) — no human trials have been reported yet.
- 03AI was used to identify T-cell epitopes (molecular targets that train the immune system) to improve vaccine design.
- 04Evaxion A/S, a Danish biotech, presented the findings; the source is a press release on a trade publication.
- 05If ultimately successful in humans, a CMV vaccine could reduce rates of CMV-related congenital hearing loss at a population level.
EVX-V1 uses AI-discovered T-cell epitopes to generate an immune response against CMV.
press releaseunclearCMV is linked to congenital (present-at-birth) hearing loss.
guidelinesupportedPreclinical data demonstrate EVX-V1 is effective at generating a targeted immune response.
press releasepartially supported